Drug Approval | November 23, 2022
USFDA grants priority review of BLA for dengue vaccine TAK-003
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
The company sees the business reaching $100mn
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Subscribe To Our Newsletter & Stay Updated
